Back HIV Prevention Microbicides

Microbicides

HIVR4P 2016: New Microbicide Enema Achieves High Levels of Drug in Rectal Tissues in Monkeys

Rectal microbicides that protect against HIV transmission via anal sex are a bigger technical challenge than vaginal ones. The rectal lining is more delicate than the vaginal lining, so safety has been an issue; research has shown that many of the gel formulations used in lubricants damage rectal cells and may actually enhance HIV transmission.

alt

Read more:

Coverage of HIV Research for Prevention Conference (HIVR4P 2016)

HIVandHepatitis.com coverage of the 2016 HIV Research for Prevention Conference (HIVR4P 2016), October 17-21, in Chicago.

Conference highlights include current and experimental pre-exposure prophylaxis (PrEP), microbicide rings and other options, and investigational HIV vaccines.

Full listing of coverage by topic

HIVR4P 2016 website

10/22/16

alt

CROI 2016: Maraviroc May Work as PrEP in a Combination, but Probably Not Alone

Two studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) last week in Boston outlined the first findings from the NEXT-PrEP study, otherwise known as HPTN 069. What NEXT-PrEP has discovered so far indicates that the drug maraviroc (Selzentry) could have a role in pre-exposure prophylaxis, or PrEP, when used alongside either tenofovir or emtricitabine (the component drugs in Truvada), but is not potent enough to act as PrEP by itself.

alt

Read more:

NIAID To Fund Follow-Up Study of Dapivirine Vaginal Ring for HIV Prevention

The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health, will support an open-label continuation study of the dapivirine vaginal ring that demonstrated modest protection against HIV infection, especially among older women, in 2 clinical trials in Africa, as reported at the recent Conference on Retroviruses and Opportunistic Infections in Boston.

alt

Read more:

CROI 2016: Studies Look at Condom Use in IPERGAY French PrEP Trial

An analysis of condom use in the placebo-controlled phase of the French IPERGAY trial of intermittent pre-exposure prophylaxis (PrEP), presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) last week in Boston, found that just over half of the participants had high levels of PrEP use but rarely used condoms, and about a quarter were "belt-and-braces" users who had high levels of both PrEP and condom use. However, this left about 1 in 6 trial participants who had low levels of use of both PrEP and condoms. While their condom use did not change, in a minority of this group their PrEP use declined significantly during the study.

alt

Read more: